Table 1 Baseline characteristics and therapy of study participants according to diabetic state
|  | Non T2DM (n = 6474) | T2DM (n = 820) | P-value |
|---|---|---|---|
Females, % | 27.1 | 43.1 | <0.001 |
Age | 62.3 ± 12.0 | 64.7 ± 9.9 | <0.001 |
Systolic blood pressure | 126.5 ± 25.1 | 128.1 ± 26.0 | 0.039 |
Admission heart rate | 77.2 ± 17.8 | 82.2 ± 19.9 | <0.001 |
Anterior ST Elevation, % | 53.4 | 52.6 | 0.633 |
Killip class II-IV, % | 17.1 | 24.8 | <0.001 |
Glucose Level, mmol/L | 7.9 ± 3.6 | 13.2 ± 5.5 | <0.001 |
Previous medical history | |||
Hypertension, % | 38.5 | 57.4 | <0.001 |
Myocardial Infarction, % | 7.5 | 12.2 | <0.001 |
Heart failure, % | 2.2 | 6.3 | <0.001 |
Stroke, % | 8.4 | 16.5 | <0.001 |
Therapeutic measures | |||
PCI, % | 10.9 | 16.9 | <0.001 |
Thrombolytic therapy | 53.3 | 45.1 | <0.001 |
Insulin | 11.5 | 40.2 | <0.001 |
β-blockers, % | 62.1 | 63.3 | 0.506 |
ACEI, % | 71.8 | 73.3 | 0.367 |
Lipid-lowering drugs, % | 71.1 | 72.6 | 0.377 |